Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 630 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... April 1, 2022 What Should People With Cancer Know About Alkaline Water? February 16, 2021 Noninferiority of OS with 3 Months Compared to 6 Months of... January 20, 2026 Load more HOT NEWS Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... EMA Recommends Extension of Indications for Inotuzumab Ozogamicin Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over...
